The anti-obesity medication stock is way up, and there could be more fuel in the tank.
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.
NVO earnings call for the period ending March 31, 2024.
Novo Nordisk (NVO), known for its popular weight-loss drug Wegovy, has seen its shares surge by more than 350% since 2020, yet it continues to trade at a 30% discount to its main U.S. competitor, Eli Lilly...
We also look at the "treasure hunt" economy.
Eli Lilly (LLY) has boosted its 2024 sales forecast by $2 billion, fueled by unprecedented demand for its innovative weight-loss drug, Zepbound, along with its diabetes treatment, Mounjaro. The surge in...
Novo Nordisk stock has surged, outperforming the market this year. Here's why it still looks like a buy right now.
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.